Novel Cholesterol Drug Outperforms Existing Treatments
The oral PCSK9 inhibitor achieved a mean LDL-C reduction of -64.6% from baseline, substantially outperforming bempedoic acid (-6.3%), ezetimibe (-27.8%), and combination therapy (-36.5%).
Loading posts...